Conflicts of Interest: Within the past 4 years, Dr. David W. Dodick has served on advisory boards, has consulted for, and received travel reimbursement from Allergan, Alder, Amgen, Pfizer, Merck, Coherex, Ferring, Neurocore, Neuralieve, Neuraxon, NuPathe Inc., MAP, SmithKlineBeecham, Boston Scientific, Medtronic, Inc., Nautilus, Eli Lilly & Company, Novartis, Colucid, GlaxoSmithKline, Autonomic Technologies Inc., MAP Pharmaceuticals, Inc., Zogenix, Inc., Impax Laboratories, Inc., Bristol Myers Squibb, Nevro Corporation, Arteaus, and Ethicon – Johnson & Johnson. Dr. Todd Schwedt has received research funding from the National Institutes of Health (NIH), the National Headache Foundation, American Headache Society, and Merck, Inc. He has participated as an investigator in clinical trials sponsored by Allergan, GSK, AGA Medical, and Optinose US Inc. He has consulted for Allergan, Merck, Pfizer, Zogenix, Supernus, and MAP.
Education and Decision Making at the Time of Triptan Prescribing: Patient Expectations vs Actual Practice
Article first published online: 11 FEB 2014
© 2014 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 54, Issue 4, pages 698–708, April 2014
How to Cite
Mathew, P. G., Pavlovic, J. M., Lettich, A., Wells, R. E., Robertson, C. E., Mullin, K., Charleston IV, L., Dodick, D. W. and Schwedt, T. J. (2014), Education and Decision Making at the Time of Triptan Prescribing: Patient Expectations vs Actual Practice. Headache: The Journal of Head and Face Pain, 54: 698–708. doi: 10.1111/head.12308
Funding: American Headache Society. Supported in part by a research grant from the Investigator Initiated Studies Program of Merck & Co., Inc. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck & Co., Inc.
- Issue published online: 2 APR 2014
- Article first published online: 11 FEB 2014
- Manuscript Accepted: 28 NOV 2013
- Investigator Initiated Studies Program of Merck & Co., Inc